Drug
HS 10234
HS 10234: highest development phase Phase 3, developed by Hansoh Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| HS-10234 NCT03903796 | Phase 3 | Chronic HBV Infection |
| HS-10234 NCT04477096 | Phase 1 | Healthy Subjects |
Latest
No recent events.
Follow HS 10234 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.